论文部分内容阅读
靶向肿瘤血管系统作为肿瘤治疗的策略已经取得了很好的临床疗效。目前上市的药物主要是抑制肿瘤的血管新生,而肿瘤血管具有的分级不规则、网络混乱等特点使得靶向既存的肿瘤血管成为可能。小分子肿瘤血管破坏剂是近年来出现的一类靶向既存血管系统的化合物,该类化合物可以快速、选择性地破坏既存的肿瘤血管网络从而引发肿瘤的坏死。目前已经有多种小分子肿瘤血管破坏剂进入临床前和临床评价,其显示的良好的体内外抗肿瘤效果为肿瘤的治疗提供了新的策略。文中综述小分子血管破坏剂的作用效果、作用机制和临床研究进展,深入理解其具体作用机制对于这类药物的开发具有重要的意义。
Targeting the tumor vasculature as a strategy for oncology has yielded good clinical outcomes. Currently listed drugs are mainly to inhibit tumor angiogenesis, and tumor blood vessels with irregular grading, network chaos and other characteristics make it possible to target the existing tumor blood vessels. Small molecule tumor vaso-vasoconstrictor is a kind of compound that has emerged in recent years to target the existing vascular system. These compounds can quickly and selectively destroy the existing tumor blood vessel network and induce tumor necrosis. There are a variety of small molecule tumor vaso-vasospasm that are currently in clinical and clinical evaluation. The results show that the good anti-tumor effect in vitro and in vivo provides a new strategy for the treatment of cancer. This review summarizes the effect, mechanism of action and clinical progress of small molecule vascular disruptors. It is of great importance to understand their specific mechanism of action for the development of these drugs.